MutY-Homolog (MYH) inhibition reduces pancreatic cancer cell growth and increases chemosensitivity.

PubWeight™: 0.75‹?›

🔗 View Article (PMID 27999205)

Published in Oncotarget on February 07, 2017

Authors

George Sharbeen1, Janet Youkhana1, Amanda Mawson1, Joshua McCarroll2,3, Andrea Nunez1, Andrew Biankin4,5, Amber Johns5, David Goldstein1, Phoebe Phillips1,3

Author Affiliations

1: Pancreatic Cancer Translational Research Group, Lowy Cancer Research Centre, Prince of Wales Clinical School, University of New South Wales, Sydney, Australia.
2: Children's Cancer Institute, Lowy Cancer Research Centre, University of New South Wales, Sydney, Australia.
3: Australian Centre for NanoMedicine, University of New South Wales, Sydney, Australia.
4: Wolfson Wohl Cancer Research Centre, Institute of Cancer Sciences, University of Glasgow, Bearsden, Glasgow, Scotland, United Kingdom.
5: The Kinghorn Cancer Centre, Cancer Program, Garvan Institute of Medical Research, Darlinghurst, Sydney, Australia.

Articles cited by this

Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science (2009) 49.82

Cancer statistics, 2016. CA Cancer J Clin (2016) 32.95

Pancreatic cancer. N Engl J Med (2010) 13.88

Pancreatic cancer. Lancet (2011) 8.54

Oxidative DNA damage: mechanisms, mutation, and disease. FASEB J (2003) 7.21

8-Hydroxyguanine, an abundant form of oxidative DNA damage, causes G----T and A----C substitutions. J Biol Chem (1992) 6.20

Whole genomes redefine the mutational landscape of pancreatic cancer. Nature (2015) 4.01

Oxygen sensing by mitochondria at complex III: the paradox of increased reactive oxygen species during hypoxia. Exp Physiol (2006) 3.61

Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin (2016) 2.93

Recent progress in pancreatic cancer. CA Cancer J Clin (2013) 2.88

Stereospecific targeting of MTH1 by (S)-crizotinib as an anticancer strategy. Nature (2014) 2.39

Triptolide induces pancreatic cancer cell death via inhibition of heat shock protein 70. Cancer Res (2007) 2.27

MTH1 inhibition eradicates cancer by preventing sanitation of the dNTP pool. Nature (2014) 2.11

Redox mechanisms switch on hypoxia-dependent epithelial-mesenchymal transition in cancer cells. Carcinogenesis (2008) 2.05

Identification of human MutY homolog (hMYH) as a repair enzyme for 2-hydroxyadenine in DNA and detection of multiple forms of hMYH located in nuclei and mitochondria. Nucleic Acids Res (2000) 2.00

Chemotherapy-associated oxidative stress: impact on chemotherapeutic effectiveness. Integr Cancer Ther (2004) 1.84

Anoikis resistance: an essential prerequisite for tumor metastasis. Int J Cell Biol (2012) 1.67

Human MutY homolog, a DNA glycosylase involved in base excision repair, physically and functionally interacts with mismatch repair proteins human MutS homolog 2/human MutS homolog 6. J Biol Chem (2002) 1.60

hMYH cell cycle-dependent expression, subcellular localization and association with replication foci: evidence suggesting replication-coupled repair of adenine:8-oxoguanine mispairs. Nucleic Acids Res (2001) 1.34

MUTYH-null mice are susceptible to spontaneous and oxidative stress induced intestinal tumorigenesis. Cancer Res (2007) 1.30

Base excision repair and cancer. Cancer Lett (2012) 1.23

An 8-oxo-guanine repair pathway coordinated by MUTYH glycosylase and DNA polymerase lambda. Proc Natl Acad Sci U S A (2009) 1.23

Nutrient deprivation induces the Warburg effect through ROS/AMPK-dependent activation of pyruvate dehydrogenase kinase. Biochim Biophys Acta (2013) 1.03

MUTYH prevents OGG1 or APEX1 from inappropriately processing its substrate or reaction product with its C-terminal domain. Nucleic Acids Res (2004) 1.01

Role of pancreatic stellate cells in chemoresistance in pancreatic cancer. Front Physiol (2014) 1.00

Warburg effect increases steady-state ROS condition in cancer cells through decreasing their antioxidant capacities (anticancer effects of 3-bromopyruvate through antagonizing Warburg effect). Med Hypotheses (2013) 0.93

MUTYH DNA glycosylase: the rationale for removing undamaged bases from the DNA. Front Genet (2013) 0.92

Potential use of the anti-inflammatory drug, sulfasalazine, for targeted therapy of pancreatic cancer. Curr Oncol (2010) 0.90

Potential applications of nanotechnology for the diagnosis and treatment of pancreatic cancer. Front Physiol (2014) 0.90

βIII-tubulin: a novel mediator of chemoresistance and metastases in pancreatic cancer. Oncotarget (2015) 0.90

Knock-down of human MutY homolog (hMYH) decreases phosphorylation of checkpoint kinase 1 (Chk1) induced by hydroxyurea and UV treatment. BMB Rep (2011) 0.89

Mammalian MutY homolog (MYH or MUTYH) protects cells from oxidative DNA damage. DNA Repair (Amst) (2013) 0.88

Effective delivery of siRNA into cancer cells and tumors using well-defined biodegradable cationic star polymers. Mol Pharm (2013) 0.84

Dual targeting of the thioredoxin and glutathione antioxidant systems in malignant B cells: a novel synergistic therapeutic approach. Exp Hematol (2014) 0.81

MUTYH, an adenine DNA glycosylase, mediates p53 tumor suppression via PARP-dependent cell death. Oncogenesis (2014) 0.80

A Rationally Optimized Nanoparticle System for the Delivery of RNA Interference Therapeutics into Pancreatic Tumors in Vivo. Biomacromolecules (2016) 0.78

Exploiting base excision repair to improve therapeutic approaches for pancreatic cancer. Front Nutr (2015) 0.78

SIRT6 protein deacetylase interacts with MYH DNA glycosylase, APE1 endonuclease, and Rad9-Rad1-Hus1 checkpoint clamp. BMC Mol Biol (2015) 0.78

MYH polyposis syndrome: clinical findings, genetics issues and management. Clin Transl Oncol (2014) 0.77